Neoadjuvant Palbociclib on ER+ Breast Cancer (N007): Clinical Response and EndoPredict Value

Endocrine-Related Cancer - United Kingdom
doi 10.1530/erc-17-0396
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Bioscientifica

Related search

Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer

Journal of Medical – Clinical Research & Reviews
2019English

Complete Response of Palbociclib in Metastatic Breast Cancer Patient: A Case Report

Biomedical Research and Therapy
BiochemistryMedicineGeneticsMolecular Biology
2018English

Value of TP53 Status for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis

PLoS ONE
Multidisciplinary
2012English

Validation of the 21-Gene Test as a Predictor of Clinical Response to Neoadjuvant Hormonal Therapy for ER+, HER2-negative Breast Cancer: The TransNEOS Study

Breast Cancer Research and Treatment
Cancer ResearchOncology
2018English

Evaluation of Clinical and Pathological Response After Two Cycles of Neoadjuvant Chemotherapy on Sudanese Patients With Locally Advanced Breast Cancer

Ethiopian journal of health sciences
Medicine
2014English

Correction: Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery

Cancer Discovery
Oncology
2019English

Relevance of Pathological Complete Response After Neoadjuvant Therapy for Breast Cancer

Breast Cancer: Basic and Clinical Research
Cancer ResearchOncology
2016English

Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer

Breast Care
SurgeryOncology
2016English

Comedications Influence Immune Infiltration and Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer

OncoImmunology
OncologyAllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy